Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T75890
|
||||
Former ID |
TTDR01187
|
||||
Target Name |
Dihydropyrimidine dehydrogenase [NADP+]
|
||||
Gene Name |
DPYD
|
||||
Synonyms |
DHPDHase; DPD; Dihydropyrimidine dehydrogenase; Dihydrothymine dehydrogenase; Dihydrouracil dehydrogenase; DPYD
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Cancer [ICD9: 140-229; ICD10: C00-C96] | ||||
Hyperlipidaemia [ICD9: 272.0-272.4; ICD10: E78] | |||||
Unspecified [ICD code not available] | |||||
Function |
Involved in pyrimidine base degradation and catalyzes the reduction of uracil and thymine. also involved the degradation of the chemotherapeutic drug 5-fluorouracil.
|
||||
BioChemical Class |
Dihydropyrimidine dehydrogenase
|
||||
UniProt ID | |||||
EC Number |
EC 1.3.1.2
|
||||
Sequence |
MAPVLSKDSADIESILALNPRTQTHATLCSTSAKKLDKKHWKRNPDKNCFNCEKLENNFD
DIKHTTLGERGALREAMRCLKCADAPCQKSCPTNLDIKSFITSIANKNYYGAAKMIFSDN PLGLTCGMVCPTSDLCVGGCNLYATEEGPINIGGLQQFATEVFKAMSIPQIRNPSLPPPE KMSEAYSAKIALFGAGPASISCASFLARLGYSDITIFEKQEYVGGLSTSEIPQFRLPYDV VNFEIELMKDLGVKIICGKSLSVNEMTLSTLKEKGYKAAFIGIGLPEPNKDAIFQGLTQD QGFYTSKDFLPLVAKGSKAGMCACHSPLPSIRGVVIVLGAGDTAFDCATSALRCGARRVF IVFRKGFVNIRAVPEEMELAKEEKCEFLPFLSPRKVIVKGGRIVAMQFVRTEQDETGKWN EDEDQMVHLKADVVISAFGSVLSDPKVKEALSPIKFNRWGLPEVDPETMQTSEAWVFAGG DVVGLANTTVESVNDGKQASWYIHKYVQSQYGASVSAKPELPLFYTPIDLVDISVEMAGL KFINPFGLASATPATSTSMIRRAFEAGWGFALTKTFSLDKDIVTNVSPRIIRGTTSGPMY GPGQSSFLNIELISEKTAAYWCQSVTELKADFPDNIVIASIMCSYNKNDWTELAKKSEDS GADALELNLSCPHGMGERGMGLACGQDPELVRNICRWVRQAVQIPFFAKLTPNVTDIVSI ARAAKEGGANGVTATNTVSGLMGLKSDGTPWPAVGIAKRTTYGGVSGTAIRPIALRAVTS IARALPGFPILATGGIDSAESGLQFLHSGASVLQVCSAIQNQDFTVIEDYCTGLKALLYL KSIEELQDWDGQSPATVSHQKGKPVPRIAELMDKKLPSFGPYLEQRKKIIAENKIRLKEQ NVAFSPLKRNCFIPKRPIPTIKDVIGKALQYLGTFGELSNVEQVVAMIDEEMCINCGKCY MTCNDSGYQAIQFDPETHLPTITDTCTGCTLCLSVCPIVDCIKMVSRTTPYEPKRGVPLS VNPVC |
||||
Drugs and Mode of Action | |||||
Inhibitor | (5s)-5-Iododihydro-2,4(1h,3h)-Pyrimidinedione | Drug Info | [551393] | ||
5-Fluorouracil | Drug Info | [535468] | |||
5-Iodouracil | Drug Info | [551393] | |||
6-Carboxymethyluracil | Drug Info | [551393] | |||
Flavin-Adenine Dinucleotide | Drug Info | [551393] | |||
Modulator | Eniluracil | Drug Info | [525898] | ||
FL-386 | Drug Info | [531635], [533903] | |||
RO-09-4889 | Drug Info | [527031], [531635] | |||
Uracil | Drug Info | [1572605] | |||
Pathways | |||||
BioCyc Pathway | Pyrimidine ribonucleosides degradation | ||||
Thymine degradation | |||||
Uracil degradation | |||||
KEGG Pathway | Pyrimidine metabolism | ||||
beta-Alanine metabolism | |||||
Pantothenate and CoA biosynthesis | |||||
Drug metabolism - other enzymes | |||||
Metabolic pathways | |||||
PANTHER Pathway | Pyrimidine Metabolism | ||||
PathWhiz Pathway | Beta-Alanine Metabolism | ||||
Pyrimidine Metabolism | |||||
WikiPathways | Metabolism of nucleotides | ||||
Fluoropyrimidine Activity | |||||
References | |||||
Ref 525898 | Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul;9(7):1635-49. | ||||
Ref 525898 | Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul;9(7):1635-49. | ||||
Ref 527031 | Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889. Clin Cancer Res. 2004 Apr 1;10(7):2327-35. | ||||
Ref 531635 | Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. | ||||
Ref 533903 | Effects of FL-386 on faecal lipid excretion in humans. J Int Med Res. 1993 Sep-Oct;21(5):225-33. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.